

Sec.		Sec.	
342.	Adulterated food.	356c-1.	Annual reporting on drug shortages.
343.	Misbranded food.	356d.	Coordination; task force and strategic plan.
343-1.	National uniform nutrition labeling.	356e.	Drug shortage list.
343-2.	Dietary supplement labeling exemptions.	356f.	Hospital repackaging of drugs in shortage.
343-3.	Disclosure.	356g.	Standards for regenerative medicine and regenerative advanced therapies.
343a.	Repealed.	356h.	Competitive generic therapies.
344.	Emergency permit control.	356i.	Prompt reports of marketing status.
345.	Regulations making exemptions.	356j.	Discontinuance or interruption in the production of medical devices.
346.	Tolerances for poisonous or deleterious substances in food; regulations.	357.	Qualification of drug development tools.
346a.	Tolerances and exemptions for pesticide chemical residues.	358.	Authority to designate official names.
346b.	Authorization of appropriations.	359.	Nonapplicability of subchapter to cosmetics.
347.	Intrastate sales of colored oleomargarine.	360.	Registration of producers of drugs or devices.
347a.	Congressional declaration of policy regarding oleomargarine sales.	360a.	Clinical trial guidance for antibiotic drugs.
347b.	Contravention of State laws.	360a-1.	Clinical trials.
348.	Food additives.	360a-2.	Susceptibility test interpretive criteria for microorganisms.
349.	Bottled drinking water standards; publication in Federal Register.	360b.	New animal drugs.
350.	Vitamins and minerals.	360b-1.	Priority zoonotic animal drugs.
350a.	Infant formulas.	360c.	Classification of devices intended for human use.
350b.	New dietary ingredients.	360c-1.	Reporting.
350c.	Maintenance and inspection of records.	360d.	Performance standards.
350d.	Registration of food facilities.	360e.	Premarket approval.
350e.	Sanitary transportation practices.	360e-1.	Pediatric uses of devices.
350f.	Reportable food registry.	360e-3.	Breakthrough devices.
350g.	Hazard analysis and risk-based preventive controls.	360f.	Banned devices.
350h.	Standards for produce safety.	360g.	Judicial review.
350i.	Protection against intentional adulteration.	360g-1.	Agency documentation and review of significant decisions regarding devices.
350j.	Targeting of inspection resources for domestic facilities, foreign facilities, and ports of entry; annual report.	360h.	Notification and other remedies.
350k.	Laboratory accreditation for analyses of foods.	360h-1.	Program to improve the device recall system.
350l.	Mandatory recall authority.	360i.	Records and reports on devices.
350l-1.	Annual report to Congress.	360j.	General provisions respecting control of devices intended for human use.
SUBCHAPTER V—DRUGS AND DEVICES		360k.	State and local requirements respecting devices.
PART A—DRUGS AND DEVICES		360l.	Postmarket surveillance.
351.	Adulterated drugs and devices.	360m.	Accredited persons.
352.	Misbranded drugs and devices.	360n.	Priority review to encourage treatments for tropical diseases.
353.	Exemptions and consideration for certain drugs, devices, and biological products.	360n-1.	Priority review for qualified infectious disease products.
353a.	Pharmacy compounding.	PART B—DRUGS FOR RARE DISEASES OR CONDITIONS	
353a-1.	Enhanced communication.	360aa.	Recommendations for investigations of drugs for rare diseases or conditions.
353b.	Outsourcing facilities.	360bb.	Designation of drugs for rare diseases or conditions.
353c.	Prereview of television advertisements.	360cc.	Protection for drugs for rare diseases or conditions.
353d.	Process to update labeling for certain generic drugs.	360dd.	Open protocols for investigations of drugs for rare diseases or conditions.
354.	Veterinary feed directive drugs.	360ee.	Grants and contracts for development of drugs for rare diseases and conditions.
355.	New drugs.	360ff.	Priority review to encourage treatments for rare pediatric diseases.
355-1.	Risk evaluation and mitigation strategies.	360ff-1.	Targeted drugs for rare diseases.
355-2.	Actions for delays of generic drugs and biosimilar biological products.	PART C—ELECTRONIC PRODUCT RADIATION CONTROL	
355a.	Pediatric studies of drugs.	360hh.	Definitions.
355b.	Adverse-event reporting.	360ii.	Program of control.
355c.	Research into pediatric uses for drugs and biological products.	360jj.	Studies by Secretary.
355c-1.	Report.	360kk.	Performance standards for electronic products.
355d.	Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers.	360ll.	Notification of defects in and repair or replacement of electronic products.
355e.	Pharmaceutical security.	360mm.	Imports.
355f.	Extension of exclusivity period for new qualified infectious disease products.	360nn.	Inspection, records, and reports.
355g.	Utilizing real world evidence.	360oo.	Prohibited acts.
355h.	Regulation of certain nonprescription drugs that are marketed without an approved drug application.	360pp.	Enforcement.
356.	Expedited approval of drugs for serious or life-threatening diseases or conditions.	360qq.	Repealed.
356-1.	Accelerated approval of priority countermeasures.	360rr.	Federal-State cooperation.
356a.	Manufacturing changes.	360ss.	State standards.
356b.	Reports of postmarketing studies.	PART D—DISSEMINATION OF TREATMENT INFORMATION	
356c.	Discontinuance or interruption in the production of life-saving drugs.	360aaa to 360aaa-6. Omitted.	

Sec.		Sec.	
	PART E—GENERAL PROVISIONS RELATING TO DRUGS AND DEVICES	363.	Regulations making exemptions.
360bbb.	Expanded access to unapproved therapies and diagnostics.	364.	Repealed.
360bbb-0.	Expanded access policy required for investigational drugs.		SUBCHAPTER VII—GENERAL AUTHORITY
360bbb-0a.	Investigational drugs for use by eligible patients.		PART A—GENERAL ADMINISTRATIVE PROVISIONS
360bbb-1.	Dispute resolution.	371.	Regulations and hearings.
360bbb-2.	Classification of products.	372.	Examinations and investigations.
360bbb-3.	Authorization for medical products for use in emergencies.	372a.	Transferred.
360bbb-3a.	Emergency use of medical products.	373.	Records.
360bbb-3b.	Products held for emergency use.	374.	Inspection.
360bbb-3c.	Expedited development and review of medical products for emergency uses.	374a.	Inspections relating to food allergens.
360bbb-4.	Countermeasure development, review, and technical assistance.	375.	Publicity.
360bbb-4a.	Priority review to encourage treatments for agents that present national security threats.	376.	Examination of sea food on request of packer; marking food with results; fees; penalties.
360bbb-4b.	Medical countermeasure master files.	377.	Revision of United States Pharmacopeia; development of analysis and mechanical and physical tests.
360bbb-5.	Critical Path Public-Private Partnerships.	378.	Advertising of foods.
360bbb-6.	Risk communication.	379.	Confidential information.
360bbb-7.	Notification.	379a.	Presumption of existence of jurisdiction.
360bbb-8.	Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments.	379b.	Consolidated administrative and laboratory facility.
360bbb-8a.	Optimizing global clinical trials.	379c.	Transferred.
360bbb-8b.	Use of clinical investigation data from outside the United States.	379d.	Automation of Food and Drug Administration.
360bbb-8c.	Patient participation in medical product discussion.	379d-1.	Conflicts of interest.
360bbb-8d.	Notification, nondistribution, and recall of controlled substances.	379d-2.	Policy on the review and clearance of scientific articles published by FDA employees.
	PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES	379d-3.	Streamlined hiring authority.
360ccc.	Conditional approval of new animal drugs for minor use and minor species and certain new animal drugs.	379d-3a.	Hiring authority for scientific, technical, and professional personnel.
360ccc-1.	Index of legally marketed unapproved new animal drugs for minor species.	379d-4.	Reporting requirements.
360ccc-2.	Designated new animal drugs for minor use or minor species.	379d-5.	Guidance document regarding product promotion using the Internet.
	PART G—MEDICAL GASES		PART B—COLORS
360ddd.	Definitions.	379e.	Listing and certification of color additives for foods, drugs, devices, and cosmetics.
360ddd-1.	Regulation of medical gases.		PART C—FEES
360ddd-2.	Inapplicability of drug fees to designated medical gases.		SUBPART 1—FREEDOM OF INFORMATION FEES
	PART H—PHARMACEUTICAL DISTRIBUTION SUPPLY CHAIN	379f.	Recovery and retention of fees for freedom of information requests.
360eee.	Definitions.		SUBPART 2—FEES RELATING TO DRUGS
360eee-1.	Requirements.	379g.	Definitions.
360eee-2.	National standards for prescription drug wholesale distributors.	379h.	Authority to assess and use drug fees.
360eee-3.	National standards for third-party logistics providers.	379h-1.	Fees relating to advisory review of prescription-drug television advertising.
360eee-4.	Uniform national policy.	379h-2.	Reauthorization; reporting requirements.
	PART I—NONPRESCRIPTION SUNSCREEN AND OTHER ACTIVE INGREDIENTS		SUBPART 3—FEES RELATING TO DEVICES
360fff.	Definitions.	379i.	Definitions.
360fff-1.	Submission of requests.	379j.	Authority to assess and use device fees.
360fff-2.	Eligibility determinations; data submission; filing.	379j-1.	Reauthorization; reporting requirements.
360fff-3.	GRASE determination.		SUBPART 4—FEES RELATING TO ANIMAL DRUGS
360fff-4.	Guidance; other provisions.	379j-11.	Definitions.
360fff-5.	Repealed.	379j-12.	Authority to assess and use animal drug fees.
360fff-6.	Non-sunscreen time and extent applications.	379j-13.	Reauthorization; reporting requirements.
360fff-7.	Report.		SUBPART 5—FEES RELATING TO GENERIC NEW ANIMAL DRUGS
360fff-8.	Sunset.	379j-21.	Authority to assess and use generic new animal drug fees.
	SUBCHAPTER VI—COSMETICS	379j-22.	Reauthorization; reporting requirements.
361.	Adulterated cosmetics.		SUBPART 6—FEES RELATED TO FOOD
362.	Misbranded cosmetics.	379j-31.	Authority to collect and use fees.
			SUBPART 7—FEES RELATING TO GENERIC DRUGS
		379j-41.	Definitions.
		379j-42.	Authority to assess and use human generic drug fees.

- Sec.
379j-43. Reauthorization; reporting requirements.
- SUBPART 8—FEES RELATING TO BIOSIMILAR BIOLOGICAL PRODUCTS
- 379j-51. Definitions.
379j-52. Authority to assess and use biosimilar biological product fees.
379j-53. Reauthorization; reporting requirements.
- SUBPART 9—FEES RELATING TO OUTSOURCING FACILITIES
- 379j-61. Definitions.
379j-62. Authority to assess and use outsourcing facility fees.
- SUBPART 10—FEES RELATING TO OVER-THE-COUNTER DRUGS
- 379j-71. Definitions.
379j-72. Authority to assess and use OTC monograph fees.
379j-73. Reauthorization; reporting requirements.
- PART D—INFORMATION AND EDUCATION
- 379k. Information system.
379k-1. Electronic format for submissions.
379l. Education.
- PART E—ENVIRONMENTAL IMPACT REVIEW
- 379o. Environmental impact.
- PART F—NATIONAL UNIFORMITY FOR NONPRESCRIPTION DRUGS AND PREEMPTION FOR LABELING OR PACKAGING OF COSMETICS
- 379r. National uniformity for nonprescription drugs.
379s. Preemption for labeling or packaging of cosmetics.
- PART G—SAFETY REPORTS
- 379v. Safety report disclaimers.
- PART H—SERIOUS ADVERSE EVENT REPORTS
- 379aa. Serious adverse event reporting for nonprescription drugs.
379aa-1. Serious adverse event reporting for dietary supplements.
- PART I—REAGAN-UDALL FOUNDATION FOR THE FOOD AND DRUG ADMINISTRATION
- 379dd. Establishment and functions of the Foundation.
379dd-1. Location of Foundation.
379dd-2. Activities of the Food and Drug Administration.
- SUBCHAPTER VIII—IMPORTS AND EXPORTS
381. Imports and exports.
382. Exports of certain unapproved products.
383. Office of International Relations.
384. Importation of prescription drugs.
384a. Foreign supplier verification program.
384b. Voluntary qualified importer program.
384c. Inspection of foreign food facilities.
384d. Accreditation of third-party auditors.
384e. Recognition of foreign government inspections.
384f. Strengthening FDA and CBP coordination and capacity.
384g. Restricting entrance of illicit drugs.
- SUBCHAPTER IX—TOBACCO PRODUCTS
387. Definitions.
387a. FDA authority over tobacco products.
387a-1. Final rule.
387b. Adulterated tobacco products.
387c. Misbranded tobacco products.
387d. Submission of health information to the Secretary.

- Sec.
387e. Annual registration.
387f. General provisions respecting control of tobacco products.
387f-1. Enforcement action plan for advertising and promotion restrictions.
387g. Tobacco product standards.
387h. Notification and other remedies.
387i. Records and reports on tobacco products.
387j. Application for review of certain tobacco products.
387k. Modified risk tobacco products.
387l. Judicial review.
387m. Equal treatment of retail outlets.
387n. Jurisdiction of and coordination with the Federal Trade Commission.
387o. Regulation requirement.
387p. Preservation of State and local authority.
387q. Tobacco Products Scientific Advisory Committee.
387r. Drug products used to treat tobacco dependence.
387s. User fees.
387t. Labeling, recordkeeping, records inspection.
387u. Studies of progress and effectiveness.
- SUBCHAPTER X—MISCELLANEOUS
391. Separability clause.
392. Exemption of meats and meat food products.
393. Food and Drug Administration.
393a. Office of Pediatric Therapeutics.
394. Scientific review groups.
395. Loan repayment program.
396. Practice of medicine.
397. Contracts for expert review.
398. Notices to States regarding imported food.
399. Grants to enhance food safety.
399a. Office of the Chief Scientist.
399b. Office of Women's Health.
399c. Improving the training of State, local, territorial, and tribal food safety officials.
399d. Employee protections.
399e. Nanotechnology.
399f. Ensuring adequate information regarding pharmaceuticals for all populations, particularly underrepresented subpopulations, including racial subgroups.
399g. Food and Drug Administration Intercenter Institutes.
399h. Grants for studying continuous drug manufacturing.
399i. Food and Drug Administration Working Capital Fund.

SUBCHAPTER I—SHORT TITLE

§ 301. Short title

This chapter may be cited as the Federal Food, Drug, and Cosmetic Act.

(June 25, 1938, ch. 675, § 1, 52 Stat. 1040.)

Statutory Notes and Related Subsidiaries

EFFECTIVE DATE; POSTPONEMENT IN CERTAIN CASES

Act June 23, 1939, ch. 242, §§ 1, 2, 53 Stat. 853, 854, provided that:

“[SEC. 1] (a) The effective date of the following provisions of the Federal Food, Drug, and Cosmetic Act is hereby postponed until January 1, 1940: Sections 402(c) [342(c) of this title]; 403(e)(1) [343(e)(1) of this title]; 403(g), (h), (i), (j), and (k) [343(g) to (k) of this title]; 501(a), (4) [351(a)(4) of this title]; 502(b), (d), (e), (f), (g), and (h) [352(b), (d) to (h) of this title]; 601(e) [361(e) of this title]; and 602(b) [362(b) of this title].

“(b) The Secretary of Agriculture shall promulgate regulations further postponing to July 1, 1940[,] the effective date of the provisions of sections 403(e)(1) [343(e)(1) of this title]; 403(g), (h), (i), (j), and (k) [343(g)